FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290659323> ?p ?o ?g. }

• W4290659323 endingPage "e2225600" @default.
• W4290659323 startingPage "e2225600" @default.
• W4290659323 abstract "Men with type 2 diabetes have an increased risk of cardiovascular disease (CVD). Meanwhile, gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer (PCa) are associated with increased risk of CVD.To evaluate the association between GnRH agonist use, PCa diagnosis per se, and CVD risk in men with type 2 diabetes.This nationwide population-based cohort study identified men with type 2 diabetes by use of data in the Prostate Cancer Data Base Sweden version 4.1 and the Swedish National Diabetes Register, with longitudinal data from 2006 to 2016. These data were used to create 2 cohorts, 1 including men with and without PCa and the other including men with PCa who received and did not receive GnRH agonists. Data analysis was conducted from January 2006 to December 2016.Treatment with GnRH agonists and PCa diagnosis were the primary exposures.Primary outcome was a 10% increase in predicted 5-year CVD risk score. Secondary outcome was worsening hypertension as defined by the European Society of Hypertension Guidelines. Cox proportional hazards regression models were used to analyze the association.The PCa exposure cohort included 5714 men (median [IQR] age, 72.0 [11.0]), and the non-PCa cohort included 28 445 men without PCa (median [IQR] age, 72.0 [11.0]). The GnRH agonist-exposure cohort included 692 men with PCa who received a GnRH agonist, compared with 3460 men with PCa who did not receive a GnRH agonist. Men with PCa receiving GnRH agonists had an increased estimated 5-year CVD risk score compared with men without PCa (hazard ratio [HR], 1.25; 95% CI, 1.16-1.36) and compared with men with PCa not receiving GnRH agonists (HR, 1.53; 95% CI, 1.35-1.74). Men receiving GnRH agonists had decreased blood pressure compared with men without PCa (HR, 0.70; 95% CI, 0.61-0.80) and compared with men with PCa not receiving GnRH agonists (HR, 0.68; 95% CI, 0.56-0.82).In this population-based cohort study, there was an increased risk of CVD in men with type 2 diabetes who received a GnRH agonist for PCa. These findings highlight the need to closely control CVD risk factors in men with type 2 diabetes treated with GnRH agonists. The association between GnRH agonist use and decreased blood pressure levels warrants further study." @default.
• W4290659323 created "2022-08-08" @default.
• W4290659323 creator A5002551277 @default.
• W4290659323 creator A5004582424 @default.
• W4290659323 creator A5009811092 @default.
• W4290659323 creator A5010401322 @default.
• W4290659323 creator A5019836957 @default.
• W4290659323 creator A5027035779 @default.
• W4290659323 creator A5033731052 @default.
• W4290659323 creator A5054505998 @default.
• W4290659323 date "2022-08-08" @default.
• W4290659323 modified "2023-10-11" @default.
• W4290659323 title "Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes" @default.
• W4290659323 cites W1554405751 @default.
• W4290659323 cites W1692684203 @default.
• W4290659323 cites W1987109043 @default.
• W4290659323 cites W2062357368 @default.
• W4290659323 cites W2064269302 @default.
• W4290659323 cites W2081052928 @default.
• W4290659323 cites W2085368059 @default.
• W4290659323 cites W2097930057 @default.
• W4290659323 cites W2098998490 @default.
• W4290659323 cites W2101614997 @default.
• W4290659323 cites W2113791652 @default.
• W4290659323 cites W2115201106 @default.
• W4290659323 cites W2128543455 @default.
• W4290659323 cites W2154067841 @default.
• W4290659323 cites W2156324321 @default.
• W4290659323 cites W2158827225 @default.
• W4290659323 cites W2165990809 @default.
• W4290659323 cites W2291685772 @default.
• W4290659323 cites W2293040502 @default.
• W4290659323 cites W2511498918 @default.
• W4290659323 cites W2513174217 @default.
• W4290659323 cites W2521042753 @default.
• W4290659323 cites W2596675526 @default.
• W4290659323 cites W2606485733 @default.
• W4290659323 cites W2888589263 @default.
• W4290659323 cites W2903145654 @default.
• W4290659323 cites W2937483840 @default.
• W4290659323 cites W2945522282 @default.
• W4290659323 cites W2947687531 @default.
• W4290659323 cites W2951756226 @default.
• W4290659323 cites W2989626047 @default.
• W4290659323 cites W2990387776 @default.
• W4290659323 cites W2996117838 @default.
• W4290659323 cites W3025887566 @default.
• W4290659323 cites W3087485153 @default.
• W4290659323 cites W3134217353 @default.
• W4290659323 cites W3139100890 @default.
• W4290659323 cites W3156566043 @default.
• W4290659323 cites W3217472410 @default.
• W4290659323 cites W4200393373 @default.
• W4290659323 cites W4205984198 @default.
• W4290659323 cites W4241778943 @default.
• W4290659323 cites W4324262198 @default.
• W4290659323 doi "https://doi.org/10.1001/jamanetworkopen.2022.25600" @default.
• W4290659323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35939302" @default.
• W4290659323 hasPublicationYear "2022" @default.
• W4290659323 type Work @default.
• W4290659323 citedByCount "1" @default.
• W4290659323 countsByYear W42906593232023 @default.
• W4290659323 crossrefType "journal-article" @default.
• W4290659323 hasAuthorship W4290659323A5002551277 @default.
• W4290659323 hasAuthorship W4290659323A5004582424 @default.
• W4290659323 hasAuthorship W4290659323A5009811092 @default.
• W4290659323 hasAuthorship W4290659323A5010401322 @default.
• W4290659323 hasAuthorship W4290659323A5019836957 @default.
• W4290659323 hasAuthorship W4290659323A5027035779 @default.
• W4290659323 hasAuthorship W4290659323A5033731052 @default.
• W4290659323 hasAuthorship W4290659323A5054505998 @default.
• W4290659323 hasBestOaLocation W42906593231 @default.
• W4290659323 hasConcept C121608353 @default.
• W4290659323 hasConcept C126322002 @default.
• W4290659323 hasConcept C134018914 @default.
• W4290659323 hasConcept C143998085 @default.
• W4290659323 hasConcept C201903717 @default.
• W4290659323 hasConcept C2780192828 @default.
• W4290659323 hasConcept C2908647359 @default.
• W4290659323 hasConcept C29456083 @default.
• W4290659323 hasConcept C50382708 @default.
• W4290659323 hasConcept C555293320 @default.
• W4290659323 hasConcept C71924100 @default.
• W4290659323 hasConcept C72563966 @default.
• W4290659323 hasConcept C99454951 @default.
• W4290659323 hasConceptScore W4290659323C121608353 @default.
• W4290659323 hasConceptScore W4290659323C126322002 @default.
• W4290659323 hasConceptScore W4290659323C134018914 @default.
• W4290659323 hasConceptScore W4290659323C143998085 @default.
• W4290659323 hasConceptScore W4290659323C201903717 @default.
• W4290659323 hasConceptScore W4290659323C2780192828 @default.
• W4290659323 hasConceptScore W4290659323C2908647359 @default.
• W4290659323 hasConceptScore W4290659323C29456083 @default.
• W4290659323 hasConceptScore W4290659323C50382708 @default.
• W4290659323 hasConceptScore W4290659323C555293320 @default.
• W4290659323 hasConceptScore W4290659323C71924100 @default.
• W4290659323 hasConceptScore W4290659323C72563966 @default.
• W4290659323 hasConceptScore W4290659323C99454951 @default.

• next